Structure-activity relationship Starfish myorelaxant peptide Pedal peptide/orcokinin-type neuropeptide Truncated analog Alanyl-substitued analog SMP-like peptide A B S T R A C T Pedal peptides and orcokinins are structurally related neuropeptides that were first discovered in protostomian invertebrates -mollusks and arthropods, respectively. Recently, pedal peptide/ocokinin (PP/OK)-type neuropeptides were discovered in a deuterostomian phylum, the echinoderms, indicating that the evolutionary origin of this neuropeptide family can be traced back to the common ancestor of bilaterian animals. Sequences comparison of PP/OK-type neuropeptides reveals several conserved residues, including N-and C-terminally located hydrophobic residues that are important for the bioactivity of orcokinin. Here we report the first comprehensive analysis of the structure-activity relationships of a PP/OK-type neuropeptide -starfish myorelaxant peptide (SMP; FGKGGAYDPLSAGFTD) from the starfish Patiria pectinifera (Phylum Echinodermata). Comparison of the bioactivity of SMP with N-terminally and/or C-terminally truncated and alanine-substituted SMP analogs revealed a core peptide (GAYDPLSAGF; SMP (5-14)) that retains the muscle-relaxing activity of SMP, albeit with reduced potency and efficacy. Within this core peptide, alanine-substitution of several residues resulted in complete or partial loss of bioactivity, whilst loss or substitution of the N-terminal phenylalanine residue of SMP also caused a substantial reduction in bioactivity. Furthermore, analysis of the bioactivity of other SMP-like peptides derived from the same precursor as SMP revealed that none of these were more potent/effective than SMP as muscle relaxants. In conclusion, we have identified key residues required for the bioactivity of a PP/OKtype neuropeptide (SMP), including hydrophobic residues located in the N-and C-terminal regions that are conserved in PP/OK-type peptides from other phyla as well as core residues that are conserved in echinoderm PP/OK-type peptides.
Introduction
Neuropeptides are neuronal signalling molecules that have key roles in the regulation of physiological processes and behaviour. The evolutionary origin of many neuropeptide signalling systems can be traced back to the common ancestor of bilaterian animals based on their occurrence in protostomes and deuterostomes [1, 2] . One of the bilaterian neuropeptide families are pedal peptide/orcokinin-type peptides [2, 3] . Pedal peptide (PP) was first discovered in the mollusk Aplysia californica and named on account of its predominant expression in the pedal ganglia of the central nervous system in this species [4] . In accordance with its expression, PP causes an increase in the contraction of pedal muscles [5] and the beating of cilia associated with the foot [6] , effects that are indicative of a physiological role in regulation of locomotor activity in gastropod mollusks. Meanwhile, orcokinin (OK) was originally isolated from neural extracts of the crayfish Orconectus limosus on account of its stimulatory effect on hindgut activity [7] . Furthermore, molecular characterization of OK-type neuropeptides in other arthropods, including insects, has revealed that multiple OK isoforms occur in each species [8] and the OK gene is alternatively spliced to give rise to two different transcripts that encode preproOK-A and -B [9] [10] [11] [12] [13] [14] . Investigation of the actions of OK-type peptides has revealed diverse physiological roles, including effects on hindgut myoactivity in the crayfish O. limosus [7] , stimulation of the prothoracic gland in the silk moth Bombyx mori [15, 16] , and regulation of circadian locomotor activity in the cockroach Leucophaea maderae [17] [18] [19] . In addition, gene silencing studies using RNAi have revealed roles of OK-type peptides in regulation of "awakening" behavior in the beetle Tribolium castaneum [13] , regulation of vitellogenin expression in the cockroach Blattella germanica [11] , and regulation of ecdysis in the kissing bug Rhodnius prolixus [9] . Thus, PP/OK-type neuropeptides have been recruited to act as stimulators of the activity of muscle and other tissues in mollusks and arthropods. Through analysis of genome/transcriptome sequence data PP/OK-type neuropeptides have also been identified in other protostomian invertebrates such as annelids and nematodes [2, 3, 20] , but nothing is known about the physiological roles of PP/OK-type peptides in these phyla.
An important advance in our understanding of the evolution of PP/ OK-type neuropeptides was the discovery of two genes/transcripts encoding PP/OK-type neuropeptide precursors in a deuterostomian invertebrate, the sea urchin Strongylocentrotus purpuratus (Phylum Echinodermata) [3] . Thus, it was established that PP/OK-type neuropeptides are a bilaterian neuropeptide family. Subsequently, a PP/OKtype neuropeptide precursor was identified in another echinoderm species, the sea cucumber Apostichopus japonicus [21] . Furthermore, an important insight into the physiological roles of PP/OK-type neuropeptides in echinoderms was made when it was discovered that a muscle-relaxing peptide in the starfish Patiria pectinifera ("starfish myorelaxant peptide"; SMP) is a PP/OK-type neuropeptide [22] . Thus, in contrast with the myoexcitatory actions of PP/OK-type neuropeptides in mollusks and arthropods, the relaxing effects of SMP on starfish muscle are indicative of a role as an inhibitory neuromodulator/neurotransmitter. Comparison of the sequence of SMP with other PP/OKtype neuropeptides reveals evolutionarily conserved structural features [3, [21] [22] [23] [24] [25] [26] [27] [28] [29] (Fig. 1) . A general characteristic of PP/OK-type peptides in both echinoderms and in protostomes are hydrophobic residues, typically phenylalanine, located proximal to or at the N-and C-termini of the peptides. A more specific feature of echinoderm PP/OK-type peptides is the core motif (D/E)-(P)-(L/M) [3, 21, 22] .
Analysis of the structure-activity relationships of orcokinin (NFDE-IDRSGFGFN) has revealed that N-terminal truncation removing the phenylalanine residue at position 2 causes a complete loss of bioactivity. Furthermore, C-terminal truncation removing the phenylalanine residue at position 12 results in a 50% loss of bioactivity, whilst Cterminal truncation to the point where residue 10 (phenylalanine) is removed causes a complete loss of bioactivity [30] . Thus, N-and Cterminal phenylalanine residues appear to be important for the bioactivity of orcokinin. It is not known, however, if the structure-activity relationships of orcokinin are generally applicable to PP/OK-type peptides in other phyla.
Nothing is known about the structure-activity relationships of SMP or other PP/OK-type peptides in echinoderms. To address these issues, here we have used in vitro pharmacology to analyze the structure-activity relationships (SAR) of SMP. The apical muscle of P. pectinifera was used as a bioassay to assess the relative importance of each amino acid residue in the sequence of SMP, testing N-and C-terminally truncated analogs of SMP and testing analogs of SMP in which each residue was substituted with an alanine (i.e. an alanine scan).
Many neuropeptide precursors, particularly in invertebrates, comprise multiple copies of structurally identical/similar peptides and this is also a feature of PP/OK-type peptide precursors, including the SMP precursor [3, 21, 25, 28] . Thus, the P. pectinifera SMP precursor comprises twelve copies of SMP (SMP a ) and multiple copies of three other structurally related peptides: SMP b (5 copies), SMP c (1 copy), and SMP d (1 copy) [22] . SMP a , SMP b , and SMP c have similar primary structures: FGKGGAYDPLSAGFTD, FGMGGAYDPLSAGFTD, and FGMGGAYDPLS-AGFTE, respectively. Lysine at the third residue is substituted with methionine in both SMP b and SMP c and aspartic acid at the sixteenth residue is substituted with glutamate in SMP c . The amino acid sequence of SMP d (GFLHGPDDPLSTSFVDGD) is quite different to the SMP sequence, but the consensus features of echinoderm PP/OK-type peptides are nevertheless present in SMP d . The occurrence of multiple copies of identical or similar peptides is a characteristic of many neuropeptide precursors, particularly in invertebrates, but its functional significance is not fully understood [31] [32] [33] [34] [35] [36] . The occurrence of multiple copies of a neuropeptide may be energetically efficient way of generating many messenger molecules from a single precursor protein. However, it is not clear why this feature has evolved in some neuropeptide precursors but not in others. Furthermore, the occurrence of "cocktails" of multiple isoforms of structurally related neuropeptides may enable neuropeptides derived from a single precursor protein to acquire different biophysical properties that are functionally important in a physiological context. To begin to address these issues for peptides derived from the P. pectinifera SMP precursor, here we have compared the bioactivity of SMP a with the bioactivity of SMP b, SMP c and SMP d . on three different in vitro preparations of starfish neuromuscular organs -apical muscle, tube feet and cardiac stomach. Furthermore, we have also compared the bioactivity of SMP a with the bioactivity of a peptide "cocktail" comprising all of the peptides derived from the SMP precursor but at concentrations corresponding to their copy number in the precursor. Fig. 1 . Multiple sequence alignment of PP/OK-type peptides in echinoderms and protostomes. White letters with grey or black highlighted boxes represent the conserved hydrophobic residues (Phe, Leu, Val, and Met) in PP/OK-type peptides. A specific feature conserved in echinoderm PP/OK-type peptides, the core motif (D/E)-(P)-(L/M), is underlined in blue. Lower case "a" in peptide sequences denotes a Cterminal amide group. Species abbreviations: Pp, Patiria pectinifera; Ar, Asterias rubens; Sp, Strongylocentrotus purpuratus; Aj, Apostichopus japonicus; Ac, Aplysia californica; Pd, Platynereis dumerilii; Ce, Caenorhabditis elegans; Nv, Nasonia vitripennis; Pc, Procambrus clarkii; Bg, Blattella germanica. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Materials and methods

Animals
Live specimens of the starfish Patiria pectinifera were collected at Cheongsapo of Busan, Korea, and maintained in a recirculating seawater system at 15°C until use. The animals were fed once every three days with live manila clam, Ruditapes philippinarum. Approval by the local institution/ethics committee was not required for this work because experimental work on starfish is not subject to regulation.
Peptide synthesis and purification
SMP (SMP a ), SMP-like peptides (SMP b , SMP c , and SMP d ) derived from the P. pectinifera SMP precursor, N-and C-terminal truncated analogs of SMP, alanyl-substituted analogs of SMP, and a shortened SMP analog with alanyl-substitution were synthesized by a conventional solid-phase method with Fmoc-protected amino acids and coupling reagents, 1-hydroxybenzotriazole (HOBT) and N,N-diisopropylcarbodimide (DIPCI), using a peptide synthesizer (PSSM-8, Shimadzu), as described previously [22] . The synthetic peptides were first subjected to reversed phase (RP)-HPLC on a semi-preparative Vydac 218TP510 Protein & Peptide C18 column (300 Å, 5 μm, 9.2 × 250 mm, USA). Elution was performed with a linear gradient of 10-30% acetonitrile/0.1% trifluoroacetic acid (TFA) at a flow rate of 3.0 ml/min for 40 min. The peptides were lyophilized and re-chromatographed on an analytical Vydac 218TP54 Protein & Peptide C18 column (300 Å, 5 μm, 4.6 × 250 mm, USA) with an adequate acetonitrile gradient. Each purified peptide was analyzed on the same analytical column with isocratic conditions to confirm the desired purity (> 98%). An aliquot of purified peptide were mixed with the same volume of α-cyano-4-hydroxycinnamic acid (10 mg/ml in 50% acetonitrile/0.1% TFA) and then 2 μl of each sample solution was spotted directly onto a MALDI sample plate. Molecular masses of the peptides were determined by matrix assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (Voyager-DE™ PRO spectrometer, Perseptive Biosystem) equipped with the following parameters: low mass gate set to 600 Da, mass range set to 0-6000 Da, accelerating voltage set to 20 000 V, grid voltage set to 60.5% of accelerating voltage, grid wire set to 1.0% of the accelerating voltage, and the delayed extraction time was set to 400 ns. Retention times of synthetic SMP a and SMP-like peptides (SMP b , SMP c and SMP d ) were compared on RP-HPLC (Vydac 218TP54 Protein & Peptide C18 column, 300 Å, 5 μm, 4.6 × 250 mm, USA) with a linear gradient of 5-45% acetonitrile/0.1% TFA at flow rate 1 ml/min in 40 min and truncated SMP analogs were compared on the same RP-HPLC column with a linear gradient of 10-40% acetonitrile/0.1% TFA at flow rate 1 ml/min in 30 min. The retention times of alanyl-substituted SMP analogs were compared with an isocratic elution of 20% acetonitrile/0.1% TFA at a flow rate of 1.0 ml/min on the same RP-HPLC column. The primary sequences of Nand C-terminal truncated analogs of SMP, alanyl-substituted analogs of SMP and SMP-like peptides (SMP b , SMP c and SMP d ) used in this study are listed in Tables 1, 2 and 3, respectively.
In vitro pharmacology
Three neuromuscular preparations (apical muscle, cardiac stomach, and tube feet) were dissected from P. pectinifera for investigation of the pharmacological activity of synthetic peptides according to previously reported methods [22] . Briefly, the apical muscle was cut from the aboral body wall of an arm, where the apical muscle forms a thickening of longitudinally orientated muscle that runs along the mid-line of the inner side. A piece of cardiac stomach between the oral opening and extrinsic retractor strand was obtained by removing the aboral body wall from the central disk and the proximal region. An individual whole tube foot was dissected from the arm ambulacra but without the ampulla. All muscle preparations were cut to approximately 10 mm, and both ends of the muscle preparations were tied with cotton threads. The preparations were then suspended vertically in a 2 ml polypropylene chamber containing artificial seawater (ASW) with aeration, one end being connected to a silver hook at the bottom of the chamber and the other to a force displacement transducer (Type 45196A, NEC-Sanei Instrument Ltd., Tokyo, Japan). Output from the force displacement transducer was monitored by a recorder (WR7300, GRAPHTEC CORP., Yokohama, Japan) via an amplifier (AS1302, NEC-Sanei, Tokyo, Japan), which recorded the mechanical responses of the device. Prior to testing, the muscle preparations were allowed to stabilize for about 90 min. The resting tension was adjusted to 1.0 g for apical muscle and 0.5 g for cardiac stomach and tube foot. Muscles in the chamber were allowed to equilibrate for about 30 min in ASW, during which ASW in the chamber was freshly replaced every 15 min. Pre-contraction of apical muscle, cardiac stomach or tube foot preparations was induced by applying 1 μM acetylcholine (ACh), 10 μM carbachol or 30 mM highpotassium ASW, respectively. Immediately after equilibration, the muscles were treated with test samples to measure relaxation responses, reflecting the original identification of SMP as a muscle relaxant in P. pectinifera using an in vitro muscle bioassay [22] . 
Data analysis and statistics
All data were expressed as the mean ± standard error of the mean (SEM). Concentration-response curves were fitted with nonlinear regression analysis and a sigmoidal curve of a four-parameter logistic equation with automatic outlier elimination using Prism software version 7.0 for Windows (GraphPad Software, San Diego, California, USA). The potency (EC 50 ) and the efficacy (E max ) values for each peptide were calculated from the best-fit of a sigmoidal concentration-response curve equation, where the potency (EC 50 ) is represented with pEC 50 , the negative logarithm of the half maximal effective concentration of the peptide and E max is the best-fit top value on a concentration-response curve for peptide-induced relaxation. The relative activity (RA) of a SMP analog was calculated as the ratio of the concentration of SMP and the analog peptide required to produce equivalent effects corresponding to the half-maximal relaxation of SMP. Statistical comparison of pEC 50 and E max between data sets was performed using the Extra sum-of-squares F test [37] . The effects of SMP and SMP analogs at the highest concentration tested (10 −5 M) were compared statistically using one-way analysis of variance (ANOVA) supported by Bonferroni's multiple comparisons test. P values less than 0.05 (p < 0.05) were considered as statistically significant. Generation of graphs, calculations and statistical analyses were performed using Prism software version 7.0 for Windows (GraphPad Software, San Diego, California, USA). 
Results
Effects of N-terminal truncation on the bioactivity of SMP as a muscle relaxant
The importance of the N-terminal region of SMP for its bioactivity as a relaxant of apical muscle preparations was investigated using a series of truncated analogs that were truncated up to ten residues. Molecular masses of synthetic analogs corresponded with theoretically calculated masses and the retention times of each peptide were steadily reduced in accordance with stepwise truncation of residues from the N-terminus (Table 1) . With truncation of the first four residues from the N-terminus, the efficacy and relaxing activity (at 10 −5 M) of analogs were comparable with full length SMP: thus, relative to SMP, the E max and relaxing activity (at 10 −5 M) values for SMP(2-16) were 112.4 ± 14.8% and 102.9 ± 3.6%, for SMP(3-16) were 108.3 ± 15.5% and 98.9 ± 8.4%, for SMP(4-16) were 110.6 ± 6.7% and 99.8 ± 7.3%, and for SMP(5-16) were 121.4 ± 6.2% and 113.4 ± 4.4%, respectively. However, removal of the first phenylalanine reside (Phe 1 ) in SMP(2-16) caused a significant reduction in potency (pEC 50 = −6.65 ± 0.28 M; n = 5; p < 0.0001) compared with full length SMP, whereas stepwise removal of residues to the fourth residue (Gly 4 ) did not cause any further decrease in potency ( Fig. 2A and Table 1 did not exhibit maximal muscle-relaxing activity at the high concentration tested (10 −5 M) and exhibited significantly reduced bioactivity compared to SMP. Furthermore, an analog comprising only the C-terminal six residues of SMP, SMP(11-16), had no effect on apical muscle preparations ( Fig. 2A) . Thus, the relative activity for all N-terminally truncated analogs was steadily reduced in accordance with stepwise truncation of residues from the N-terminus of full length SMP. Collectively, these experiments indicate that SMP requires at least twelve amino acids from residue Gly 5 to residue Asp 16 to exhibit the same efficacy as SMP as a relaxant of apical muscle preparations, whilst the first Phe 1 residue is required to retain potency equivalent to that of the full length SMP peptide.
Effects of C-terminal truncation on the bioactivity of SMP as a muscle relaxant
The importance of the C-terminal region of the SMP for its relaxing activity on apical muscle preparations was investigated by stepwise truncation of residues up to Ser 11 , the sixth residue from the C-terminus (Fig. 2B and (p < 0.05) were considered as statistically significant. i RA, relative activity was calculated as the ratio of the concentration of SMP and analog peptides required to produce equieffective responses to a half-maximal SMP response.
* Maximal relaxing activity was not reached at a peptide concentration of 10 −5 M. † CBD (cannot be determined) because the value was ambiguous and accurate deconvolution was not possible. Fig. 2 . Concentration-responses curves comparing the effects of SMP and truncated analogs of SMP as relaxants of the apical muscle from P. pectinifera. The effect of SMP is compared with the effects of N-terminally truncated analogs (A), C-terminally truncated analogs (B), and a minimized bioactive analog SMP(5-14) (C). Each point represents the mean ± standard error of the mean (SEM) determined from at least 4 or 5 separate experiments and the curves were fitted with nonlinear regression analysis and a sigmoidal curve of a four-parameter logistic equation with automatic outlier elimination using Prism software (ver.7.0). The percentage relaxing activity was calculated by comparing each relaxation effect with the maximal contraction of the apical muscle by 1 μM ACh. 1-15) and SMP(1-14) exhibited efficacies of 107.5 ± 7.5% and 106.3 ± 6.2%, respectively, and relaxing activities (at 10 −5 M) of 99.7 ± 2.2% and 102.9 ± 2.9%, respectively, which correspond with full length SMP. However, the potencies of SMP(1-15) and SMP (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) were approximately 22-fold (pEC 50 = −6.36 ± 0.12 M) and 9-fold (pEC 50 = −6.76 ± 0.13 M) less than that of SMP, respectively. Accurate deconvolution values could not be obtained from the sigmoidal curve of SMP (1-13) because maximal relaxation was not observed with the highest concentration tested, but removal of the third residue (Phe
14
) from the C-terminus in the analog SMP(1-13) clearly caused a drastic reduction in bioactivity, including efficacy (31.3 ± 24.8%), potency (pEC 50 = ∼−5.69 ± ∼3.30 M), and relative activity (0.00066), which were approximately 3.7 fold, 100 fold and 1 500-fold less than those of full length SMP, respectively (see SMP(1-13) concentration-response curve in Fig. 2B ). This result demonstrates that the Phe 14 residue in the C-terminal region of SMP is a critical residue for the bioactivity of full length SMP as a relaxant of the P. pectinifera apical muscle. Removal of the fourth residue (Gly
13
) from C-terminus in the analog SMP(1-12) led to an almost complete loss of activity, an effect greater than that seen with SMP(7-16), which lacks nine residues from the N-terminus. Thus, the bioactivity of SMP is more adversely affected by C-terminal truncation than by N-terminal truncation. Collectively, these data indicate that the C-terminal region of SMP, and in particular Phe 14 , is critical for the bioactivity of SMP as a muscle relaxant.
Effect of combined N-and C-terminal truncation on the bioactivity of SMP
Informed by the results from experiments with N-and C-terminal truncated analogs, an N-terminally and C-terminally truncated analog of SMP comprising ten amino acids, SMP (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , was designed, synthesized and tested on apical muscle preparations as a predicted minimal bioactive analog of SMP (Fig. 2C and Table 1 ). SMP (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) exhibited potency (pEC 50 = −4.41 ± 0.85 M) that was approximately 60-fold, 220-fold, or 2 000-fold less than SMP (5-16), SMP (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) and full length SMP, respectively. Thus, the relative activity of SMP (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) was approximately 20-fold, 50-fold, and 440-fold less than SMP (5-16), SMP (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) or full length SMP, respectively. Although the relaxing activity at 10 −5 M of SMP (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) only reached half of that of SMP (62.3 ± 5.6%), its efficacy as determined by maximal response was 150.1 ± 54.0%, which was not statistically different to that of SMP. These results indicate that SMP (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , comprising the ten amino acids from Gly 5 to Phe 14 of full length SMP, is sufficient to elicit a maximal response when tested for its relaxing activity on apical muscle preparations.
The effects of alanyl-substitution on the bioactivity of SMP
Substitution of each amino acid residue by an alanine moiety is a classical approach to investigate the contributions of individual side chains to the structural and functional properties of proteins and peptides. Therefore, to examine the importance of each residue in SMP, a series of alanyl-substituted analogs were synthesized and tested for their effectiveness as relaxants of the apical muscle from P. pectinifera (Fig. 3 and Table 2 ). SMP is a sixteen residue peptide but only fourteen alanyl-substituted analogs were synthesized and tested because alanine itself is present in the primary sequence of SMP at two positions -Ala 6 and Ala
12
. Like SMP, all of the alanyl-substituted analogs caused concentration-dependent relaxation of apical muscle preparations. The efficacies of the analogs were similar to SMP, with the exception of analogs with alanine substituted at Leu 10 , Gly 13 , and Phe
14
, which had lower efficacy and/or non-sigmoidal concentration-response curves (Fig. 3) . In comparison with SMP, a significant decrease in relaxing activity (when tested at 10 −5 M) was only observed with 10Ala-SMP (61.7 ± 4.9%; p < 0.001) and 14Ala-SMP (46.8 ± 3.8%; p < 0.0001). Substitution of five residues in the N-terminal region of SMP (Phe 1 to Gly 5 ) with alanine resulted in a significant reduction in potency (pEC 50 ) in three analogs -1Ala-SMP (pEC 50 = −6.68 ± 0.15 M; p < 0.0001), 2Ala-SMP (pEC 50 = −6.95 ± 0.40 M; p < 0.05) and 5Ala-SMP (pEC 50 = −6.89 ± 0.14 M; p < 0.0001). The lowest relative activity was exhibited by 1Ala-SMP (0.053), where Phe 1 was replaced with Ala ( Fig. 3A and Table 2 ). By contrast, drastic changes in activity were observed when alanine was substituted for residues (Tyr 7 to Leu 10 ) in the central region of SMP. All four analogs (7Ala-, 8Ala-, 9Ala-, and 10Ala-SMP) exhibited a significant reduction in potency with pEC 50 in the range −6.71 ± 0.13 M to −4.64 ± 2.8 M, corresponding to approximately 10-1 150 fold less than SMP. Among these, 10Ala-SMP in which Leu 10 is substituted with alanine exhibited a remarkably drastic decrease in the potency (pEC 50 = −4.64 ± 2.76 M) corresponding to 1 150-fold less than SMP and a relative activity 270-fold (0.0037) less than SMP (Fig. 3B and Table 2 ). The most deleterious impact on bioactivity was observed in the analog 14Ala-SMP, which exhibited an approximately 49 000-fold reduction in potency (pEC 50 = ∼−3.01 ± ∼14.18 M), and a 550-fold reduction in bioactivity (0.0018) compared to SMP (Fig. 3C and Table 2 ). The similar activity exhibited by analogs with substitution of the four residues in the N-terminal region of SMP (Phe 1 to Gly 4 ) suggests that the side chains in this region may not be intimately involved in binding with receptor proteins. However, the remarkably drastic reduction in activity caused by substitution of four residues in the central region (Tyr 7 to Leu 10 ) and Phe 14 at the Cterminus suggests that the side chains of these residues may have important roles in binding of SMP to its receptor(s).
The effects of alanyl-substitution on the bioactivity of SMP(5-14)
To further investigate the importance of the central region and residue Phe 14 for the bioactivity of SMP, analogs with alanyl-substitution of each residue in the minimized SMP(5-14) peptide were synthesized and tested at 10 −4 M on apical muscle preparations. Substitution of Gly 5 and Tyr 7 with alanine did not cause a significant reduction in bioactivity. However, substitution of residues from Asp 8 to Phe 14 with alanine caused a significant reduction in bioactivity (Fig. 4) . Thus, consistent with the results from truncation and alanyl-substitution of full-length SMP, these findings indicate that residues in the central region of SMP and the C-terminal Phe 14 of SMP are required to bind to and/or activate the SMP receptor(s) to elicit relaxation of the apical muscle of P. pectinifera.
SMP is the most potent muscle-relaxing peptide derived from the SMP precursor
The SMP precursor gives rise to SMP and three SMP-like peptides: SMP (SMP a , 12 copies), SMP b (5 copies), SMP c (1 copy), and SMP d (1 copy) (Table 3 ) [22] . Therefore, we compared the bioactivity of SMP with the other three peptides and a mixture of the four peptides (SMP cocktail ; containing SMP, SMP b , SMP c , and SMP d at a molar ratio of 12:5:1:1 corresponding to copy number in the precursor protein) at a range of concentrations on apical muscle preparations from the starfish P. pepctinifera. (Fig. 5 and Table 3 ). All four peptides and the SMP cocktail caused concentration-dependent relaxation of the apical muscle, and the efficacy (E max ), potency (pEC 50 ) and relative activity were determined ( Fig. 5A and Table 3 ). The efficacies of the four peptides and the SMP cocktail were not significantly different (p > 0.05; Table 3 ). The potencies of SMP, SMP b , and SMP cocktail were similar (pEC 50 = −7.70 ± 0.07 M, −7.53 ± 0.09 M, and −7.48 ± 0.09 M, respectively) and were significantly more potent than SMP c (pEC 50 These data indicate that, consistent with its relative abundance, SMP is functionally the most important peptide derived from the SMP precursor as a relaxant of the apical muscle from P. pectinifera.
To obtain further insights into the relative bioactivities of peptides derived from the SMP precursor, SMP a , SMP b , SMP c , SMP d and SMP cocktail were also tested on cardiac stomach and tube foot preparations from P. pectinifera (Fig. 5B) . Administration of SMP a and the other peptides caused relaxation of both preparations. However, the potency, efficacy, and relative activity of each peptide were not calculated because maximal activity was not observed at the highest concentration tested (10 −4 M), resulting in concentration-response curves that did not correspond to a sigmoidal curve with a four parametric equation. Therefore, the relaxing activities of the peptides on cardiac stomach and tube feet at 10 −5 M were used for comparison but these were found not to be significantly different (Fig. 5B ).
Discussion
Starfish myorelaxant peptide (SMP) belongs to the bilaterian family of pedal peptide/orcokinin (PP/OK)-type neuropeptides. Alignment of SMP with other PP/OK-type neuropeptides reveals interphyletic conservation of hydrophobic phenylalanine or leucine residues in the N-terminal and C-terminal regions. Furthermore, a core motif, (D/E)-(P)-(L/M), is a conserved feature of SMP-like peptides in echinoderms (Fig. 1) . However, the functional importance of these conserved residues for the bioactivity of SMP as a muscle relaxant is unknown. To address this issue here we investigated the structure-activity relationships of SMP from the starfish P. pectinifera. This is the first study to investigate the structure-activity relationships of a PP/OK-type neuropeptide in a deuterostome.
Two approaches to investigation of the structure-activity relationships of SMP were employed here: firstly, N-and/or C-terminal truncation (Table 1 and Fig. 2 ) and secondly alanine substitution (Table 2 and Fig. 3 ). It should be recognized, however, that there are limitations in these approaches toward identification of residues that are important for peptide bioactivity. The impact of alanine substitution on peptide bioactivity will to some extent be dependent on the choice of alanine as the substituting amino acid. Thus, replacement of residues that are structurally similar to alanine (e.g. glycine, valine) may have less impact on bioactivity than replacement of residues that are structurally dissimilar to alanine. So if replacement of a residue that is structurally similar to alanine has little on no impact on bioactivity, it doesn't necessarily imply that the replaced residue is not important for peptide bioactivity.
N-terminal and C-terminal truncation of SMP revealed a core peptide (GAYDPLSAGF; SMP (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) ) that retains the muscle-relaxing activity of SMP, albeit with reduced potency and efficacy. Furthermore, stepwise N-terminal or C-terminal truncation of SMP revealed dramatic reductions in bioactivity with the loss of several key residues. Thus, in the N-terminal region loss of the first residue (Phe 1 ) resulted in a tenfold reduction in potency. Accordingly, substitution of Phe 1 with alanine resulted in a twenty-fold reduction in potency and relative activity compared to SMP. However, stepwise loss of N-terminal residues up to position five (Gly 5 ) resulted in no or only slight additional reductions in potency. Loss of the C-terminal residues Thr 15 and/or Asp 16 caused an approximately ten-fold reduction in potency and relative activity, but loss of Phe 14 caused a much greater reduction in bioactivity corresponding to a relative activity of 0.00066 compared to SMP. Accordingly, substitution of Phe 14 with alanine also caused a large reduction in bioactivity that corresponded to a relative activity of 0.0018 compared to SMP. Importantly, these findings are consistent with a previous investigation of the structure-activity relationships of the crustacean neuropeptide orcokinin (NFDEIDRSGFGFN) [35] . Here Nterminal truncation removing the first two residues, including Phe 2 caused a complete loss of bioactivity, whilst C-terminal truncation removing the last two residues, including Phe 12 , caused a 50% reduction in bioactivity. Thus, experimental studies in both a protostome (orcokinin in the crayfish Orconectes limosus; [35] ) and a deuterostome (SMP in the starfish P. pectinifera; this study) have independently demonstrated the importance of N-terminal and C-terminal phenylalanines for the bioactivity of PP/OK-type peptides. These findings are consistent with the evolutionary conservation of N-terminal and C-terminal hydrophobic residues (Phe or Leu) in PP/OK-type peptides. Analysis of the core bioactive region of SMP GAYDPLSAGF also revealed the importance of several residues for the bioactivity of SMP (Fig. 4) . Thus, substitution of residues Tyr (Table 2 and Fig. 3 ). The least active of these analogs, 10Ala-SMP, is noteworthy because the presence of a hydrophobic residue in the position occupied by leucine at position ten in SMP is an evolutionarily conserved feature of all PP/OK-type peptides (Fig. 1) . Accordingly, loss of the corresponding residue (Phe) in C-terminally truncated analogs of orcokinin results in a complete loss of bioactivity [35] . Thus, together with Phe 1 and Phe
14
, Leu 10 in SMP is one of three evolutionarily conserved hydrophobic residues that have been identified as important for bioactivity in both protostomian (orcokinin) and deuterostomian (SMP) PP/ OK-type neuropeptides (Figs. 1 and 6 ). The other three residues in the core bioactive region of SMP (Tyr 7 , Asp 8 , Pro 9 ) are not conserved in protostomian PP/OK-type peptides (see Fig. 1 ). However, these residues are conserved in SMP-like peptides in other echinoderms. Therefore, these residues may be key residues in SMP that are important for receptor binding and activation.
Precursors of PP/OK-type neuropeptides comprise multiple copies of structurally identical or similar bioactive peptides. For example, the precursor of the prototypical pedal peptide in Aplysia californica (GenBank Accession number: NP_001191585.1) comprises seventeen copies of pedal peptide and one copy each of two other pedal peptidelike neuropeptides [25] and the orcokinin precursor in the crayfish Procambarus clarkii (GenBank Accession number: BAA94754.1) comprises eight copies of orcokinin and four copies of three other orcokininlike peptides [28] . Accordingly, the P. pectinifera SMP precursor comprises twelve copies of SMP (SMP a ; FGKGGAYDPLSAGFTD), five copies of SMP b (FGMGGAYDPLSAGFTD), one copy of SMP c (FGMGGAYDPL-SAGFTE) and one copy of SMP d (GFLHGPDDPLSTSFVDGD) [22] . Here we investigated the functional significance of the "cocktail" of neuropeptides derived from the SMP precursor by comparing the bioactivity of SMP (SMP a ) with the bioactivities of SMP b , SMP c , SMP d and a "cocktail" (SMP cocktail ) of all of the peptides derived from the SMP precursor mixed proportionately to peptide copy number in the precursor (Table 3 and Figs. 5 and 6 ). The potency of SMP b was not significantly different to that of SMP a but the relative activity of SMP b compared to SMP a was determined as 0.49. However, SMP b only differs from SMP a at one position -Lys 3 in SMP a is replaced with Met in SMP b .
Accordingly, substitution of Lys 3 with alanine in the SMP analog 3Ala-SMP yielded a peptide with a potency that was not significantly different to SMP and that had a relative activity of 0.38. SMP c has two amino-acid substitutions with respect to SMP a -Lys 3 and Asp 16 in SMP a are replaced with Met and Glu, respectively. SMP c exhibited a slight but significant reduction in potency compared to SMP a and relative activity of 0.39. Thus, although substitution of Asp 16 with Glu represents a conservative substitution with another amino acid, it nevertheless caused a reduction in bioactivity. The sequence SMP d is quite different to that of SMP a , with only seven of the sixteen residues in SMP a 1 corresponding to copy number in the precursor SMP [22] ) on three muscle preparations from P. pectinifera. All four peptides and the SMP cocktail caused concentration-dependent relaxing effects on the apical muscle (A). The peptides (at 10 −5 M) were also tested on cardiac stomach and tube feet preparations and "n.s." denotes that the relaxing effects of the peptides on these preparartions was not significantly different (B). Percentage relaxing activity was calculated by comparing each relaxation effect with the maximal contraction of apical muscle by 1 μM ACh, cardiac stomach by 10 μM carbachol, and tube feet by 30 mM high-potassium ASW, respectively. Data represent the mean ± SEM determined from five separate experiments. conserved in SMP d . The bioactivity of SMP d as an apical muscle relaxant was substantially less than that of SMP a , with a calculated relative activity of 0.0088. Lastly, the potency of the cocktail of SMP precursor derived peptides (SMP cocktail ) was not significantly different to that of SMP a but SMP cocktail had a relative activity of 0.8. Thus, the bioactivity of peptides derived from the SMP precursor is largely attributable to SMP a .
In conclusion, comparison of the bioactivity of analogs of SMP and SMP-like peptides derived from the SMP precursor has provided important new insights into functional significance of evolutionarily conserved residues in PP/OK-type neuropeptides. Furthermore, knowledge of the structure-activity relationships of PP/OK-type peptides may be useful in informing the design of compounds that could have applications for chemical control of invertebrate pests and parasites. An important goal for future studies will be to identify the receptor(s) that mediate the effects of PP/OK-type neuropeptides, which may enable identification of amino acids that form ligand binding sites for PP/OK-type peptides.
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